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ABSTRACT. Objective: This study aims to test whether recent in-
creases in the reported prevalence of opioid-use disorder in the United 
States occurred across all age groups (period effect), consistently only 
among younger age groups (age effect), or varied according to year of 
birth (cohort effects). Method: Joint analysis of data from the 1991-1992 
National Longitudinal Alcohol Epidemiologic Survey (NLAES) and 
the 2001-2002 National Epidemiologic Survey on Alcohol and Related 
Conditions (NESARC), focusing on individuals ages 18-57, grouped by 
10-year age intervals. Sample sizes for the present analyses were 30,846 
for the NLAES and 31,397 for the NESARC. Prevalence of lifetime and 
past-year prescription opioid-use disorder resulting from nonmedical use 
(abuse and dependence) was examined. Results: Within birth cohorts, 
prevalence of lifetime prescription opioid-use disorder increased during 
the 10 years between surveys, indicating the importance of age effects. 
In addition, lifetime and past-year prevalence of prescription opioid-use 
disorder was higher among more recent birth cohorts as compared with 
earlier birth cohorts, indicating the importance of cohort effects. Consis-
tent with a period effect, cross-cohort comparisons showed that risk for 
prescription opioid-use disorder has increased for all individuals regard-
less of their birth cohort membership from the NLAES to the NESARC 
survey. Conclusions: Findings suggest that more problems (abuse and 
dependence) may emerge as prescription opioid users get older and 
that more recent birth cohorts are at higher risk for prescription opioid 
problems. (J. Stud. Alcohol Drugs, 71, 480-487, 2010)
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THERE HAVE BEEN SUBSTANTIAL INCREASES in the availability of prescription opioids in the United 
States, as evidenced by the increase in the number of pre-
scriptions for opioids in the past 15 years (Cicero et al., 
2007; Compton and Volkow, 2006; Van Zee, 2009; Zacny 
et al., 2003). Pain medications such as prescription opioids 
can be effective when used properly, but these drugs can 
be addictive and dangerous when used improperly because 
they have a high misuse potential. One type of improper 
use is nonmedical use—defi ned as “use to get high, using 
more than prescribed, using it for indications other than 
those intended by the prescriber, or for other experiences, 
sensations, or effects beyond the boundaries of approved 
prescribing procedures or indications as dispensed” (An-
thony et al., 1994, p. 244). The development of dependence 
on prescription opioids resulting from nonmedical use is as-
sociated with adverse consequences, including comorbidity 
with other substances of abuse. Huang et al. (2006) showed 
that lifetime prescription opioid-use disorders resulting 
from nonmedical use are strongly associated with other 
prescription-drug-use disorders, alcohol-use disorders, and 
illegal-drug-use disorders.
 Evidence for increase in nonmedical use includes reports 
that nonmedical use of prescription opioids in the U.S. 
population age 18 years and older doubled within a 10-year 
time span, from 0.6% in 1991-1992 to 1.3% in 2001-2002 
(Blanco et al., 2007). The estimated prevalence of past-year 
disorders (abuse/dependence) from nonmedical prescription 
opioid use has also increased in this same period, from 0.1% 
in 1991-1992 to 0.3% in 2001-2002 (McCabe et al., 2008). 
However, studies to date have not attempted to determine 
whether more recent birth cohorts are at higher risk than 
earlier cohorts or the degree to which risk for prescription 
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opioid-use disorder resulting from nonmedical use increases 
or decreases with age. Variation by birth cohort is an impor-
tant aspect of the epidemiology of prescription opioid-use 
disorder. Cohorts at high risk for the disorder resulting from 
nonmedical use should be targeted for intervention, and 
examination of the environments unique to certain birth 
cohorts can aid in the identifi cation of etiologic factors. 
The current article uses a repeated cross-sectional approach 
(Firebaugh, 1997) to disentangle potential age, period, and 
cohort effects in prescription opioid-use disorders in the 
United States.
 Rates of prescription opioid-use disorder resulting from 
nonmedical use have been found to vary by age, with 
lifetime and past-year disorders more common among 
younger adults (Becker et al., 2008a, 2008b; Huang et al., 
2006; Martins et al., 2009). In addition, the changes in the 
prevalence of prescription opioid use and disorder are linked 
with possible infl uences of time, changes with age, or both. 
Further, the introduction of new types of prescription opioid 
compounds could increase use among the entire population, 
regardless of age (period effect), or alternatively, the uptake 
of the new compounds could vary across age. For example, 
the elderly might use new medications more for relief of 
pains attributable to aging, suggesting the presence of a 
cohort effect. It is also possible that age effects would arise 
whereby younger cohorts would be at higher risk for use at 
both time points, because there is a general tendency for 
younger people to report higher rates of psychopathology 
and substance-related problems (Grucza et al., 2008; Simon 
and VonKorff, 1992).
 Evidence for birth cohort effects in health outcomes is 
relevant for both epidemiological surveillance and etiologic 
research (Hasin et al., 2007). For surveillance, health out-
comes that differ by birth cohort should be analyzed and 
presented by year of birth rather than year of observation or 
year of death, because the latter approaches can obscure the 
interpretation of trends. For etiologic investigations, the iden-
tifi cation of particular birth cohorts with increased risk of a 
health outcome provides an anchor for hypothesis generation 
and testing regarding early life factors that may contribute to 
the development of the outcome over time.
 Analysis of data from repeated cross-sectional surveys 
facilitates such an examination by allowing change within 
birth cohorts to be disentangled from differences between 
birth cohorts (Firebaugh, 1997). This has previously been 
applied to combined data from the National Longitudinal 
Alcohol Epidemiologic Survey (NLAES; Grant, 1997) 
and National Epidemiologic Study on Alcohol and Related 
Conditions (NESARC; Grant et al., 2006) to demonstrate 
cohort differences in lifetime prevalence of alcohol use and 
dependence (Grucza et al., 2008; Keyes et al., 2008). More-
over, lifetime disorder data can be combined with past-year 
disorder estimates to analyze changes in both the number of 
users with a disorder and the persistence of disorders within 
birth cohorts. Likewise, differences in lifetime disorder and 
persistence across cohorts can be evaluated.
 In this article, we combine information from the NLAES 
and NESARC, two U.S. national surveys conducted 10 
years apart. Our goal was to test whether the increases in 
prevalence of prescription opioid-use disorder resulting from 
nonmedical use occurred across all age groups (period ef-
fect), occurred consistently only among younger age groups 
(age effect), or varied according to year of birth (cohort 
effects). To evaluate evidence for age effects, we examine 
changes within birth cohorts over the 10-year period between 
surveys. To evaluate evidence for cohort effects, we examine 
differences between similarly aged birth cohorts born 10 
years apart. To evaluate period effects, we examine whether 
changes across time are consistent across age groups. In 
addition, to assist in the comparisons of prescription opioid-
use-disorder prevalence changes within birth cohorts, we 
also report changes in the lifetime and past-year prevalence 
of nonmedical prescription opioid use within birth cohorts 
over the same period.
Method
Sample
 The NLAES was conducted in 1991-1992 (N = 42,862, 
response rate of 90%); the NESARC was conducted in 
2001-2002 (N = 43,093, response rate of 81%). Both surveys 
focused on alcohol and drug use; Diagnostic and Statisti-
cal Manual of Mental Disorders, Fourth Edition (DSM-IV; 
American Psychiatric Association, 1994) substance-use 
disorders; associated impairment; and comorbid psychi-
atric disorders in samples representative of the adult (18 
and older), noninstitutionalized, civilian population of the 
United States. Data were collected in all 50 U.S. states and 
the District of Columbia. Blacks and young adults were over-
sampled in both surveys and Hispanics were oversampled in 
the NESARC. Face-to-face interviews were administered by 
experienced lay interviewers from the U.S. Census Bureau. 
Respondents were informed about measures taken to ensure 
the confi dentiality of the information they provided and 
informed consent was obtained from all subjects. Further 
details for both surveys and comparative descriptions of 
methods are available elsewhere (Compton et al., 2004; 
Dowling et al., 2006; Grant et al., 2004; Grucza et al., 2008; 
Simoni-Wastila et al., 2004).
 Change in cohort composition as a result of differential 
mortality is a potential confounder for these analyses. Hence, 
the present analyses focuses on the subset of subjects ages 
18-57 at the time of the survey. The upper age limit of 57 
serves to mitigate the potential effects of differential mortal-
ity on cohort composition (Grucza et al., 2008). The analysis 
sample for this study includes 30,843 persons in the NLAES 
and 31,397 persons in the NESARC.
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Measures
 Both surveys used the Alcohol Use Disorder and As-
sociated Disabilities Interview Schedule-DSM-IV Version 
(AUDADIS-IV) to assess substance use and dependence 
as well as other psychiatric disorders. Nonmedical use of 
prescription opioids was described to respondents as using 
a prescription opioid: “without a prescription, in greater 
amounts, more often, or longer than prescribed, or for a 
reason other than a doctor said you should use them.” In 
both surveys, an extensive list of prescription opioids was 
shown to each respondent. The same wording was used in 
each survey and a more extensive list of specifi c prescription 
opioids is available elsewhere (Grant et al., 2006). The same 
questions were administered the same way by interviewers 
who underwent similar, extensive training (Compton et al., 
2004). To ensure equality of measurement across the NLAES 
and NESARC, prescription opioid-use disorder resulting 
from nonmedical use (abuse/dependence) was considered 
positive in both samples only if respondents in the NESARC 
used prescription opioids nonmedically 12 or more times on 
a lifetime basis (this threshold is created in the NESARC 
by combining the lifetime and past-year use variables with 
the frequency of use variables, for instance, if respondents 
used prescription opioids only in the past year, they were 
classifi ed as users only if they used prescription opioids at 
least once a month in the past 12 months; more details are 
available on request).
 Prescription opioid-use disorder resulting from nonmedi-
cal use was defi ned as per DSM-IV substance abuse and de-
pendence criteria. Test-retest reliability for AUDADIS-IV 
past-year opioid-disorders (abuse/dependence) diagnosis 
resulting from nonmedical use in general population and 
clinical settings was good to fair with a  agreement of .59 
for past-year dependence (Grant et al., 1995; Hasin et al., 
1997). From this point onward, for simplicity, prescription 
opioid disorder resulting from nonmedical use will be re-
ferred to as prescription opioid-use disorder.
 Subjects were categorized into 10-year age groups (18-27, 
28-37, 38-47, and 48-57) in both the NESARC and NLAES. 
Individuals who were 18-27 in the NLAES are from the 
same birth cohort of individuals who were 28-37 10 years 
later in the NESARC (both groups were born from approxi-
mately 1964 to 1973). Similarly, individuals who were 28-37 
in the NLAES are from the same birth cohort of individuals 
who were 38-47 in the NESARC (both groups were born 
from approximately 1954 to 1963). Cohorts born between 
1944 and 1973 were represented in both surveys, whereas 
those born between 1974 and 1983 were represented in the 
NESARC only (individuals ages 18-27 in 2001-2002), and 
those born between 1934 and 1943 were represented in the 
NLAES only (individuals 48-57 in 1991-1992).
Statistical analyses
 Because of similarities in the sampling universe, defi -
nitions of outcome variables, and other methodological 
characteristics, simultaneous analysis of the NLAES and 
NESARC constitutes a repeated cross-sectional analysis. 
When subjects from the NESARC, conducted in 2001-2002, 
are grouped by age and compared with subjects of the same 
age range from the NLAES, conducted in 1991-1992, the 
primary distinction between the two are cohort differences, 
where the ranges of birth years are offset by 10 years.
 Proper methods for the detection of age, period, and 
cohort effects have been the source of debate for decades 
(Glenn, 2005; Mason et al., 1973). We used basic descriptive 
methods to examine evidence for the presence of age, period, 
and cohort effects separately, a basic epidemiologic method 
that involves the comparison of prevalence within certain 
groups. Three comparisons were made.
 First, we evaluated evidence for age effects by examining 
changes in prevalence across age within each cohort group. 
For example, we started with the same cohort of people (e.g., 
born between 1964 and 1973) and compared the prevalence 
of prescription opioid-use disorder when they were 18-27 
years old (one cohort assessed by NLAES) with the preva-
lence obtained when they were 28-37 years old (same cohort 
assessed by NESARC). Second, we evaluated evidence for 
cohort effects by examining changes in prevalence across 
cohorts within each age group. For example, the prevalence 
in the 1964-1973 NLAES birth cohort was compared with 
the similarly aged (i.e., 18-27 years) 1974-1983 NESARC 
birth cohort. Third, we evaluated evidence for period effects 
by examining the prevalence of prescription opioid-use 
disorder across all age groups between the NLAES and the 
NESARC. For example, period effects would be implicated 
if the prevalence is higher for all age groups in the NESARC 
compared with the NLAES. These prevalences were calcu-
lated for four outcomes: lifetime disorder among the overall 
population within each cohort, lifetime disorder among life-
time users within each cohort, past-year disorder among the 
overall population within each cohort, and past-year disorder 
among lifetime users within each cohort.
 Effects were statistically evaluated on both the additive 
and multiplicative scale. On the additive scale, we provided 
proportions with 95% confi dence intervals and annotations 
for unadjusted p values. Differences in proportion on the 
additive scale are most directly relevant for public health, 
because they provide a measure of the absolute risk increase 
associated with a particular exposure (in this case, age and 
birth cohort). On the multiplicative scale, we provided odds 
ratios (ORs) and 95% confi dence intervals (CIs) derived 
from weighted logistic regressions to examine overall 
cross-cohort comparisons. Differences in proportion on the 
multiplicative scale are most directly relevant for etiologic 
investigation, because they provide a measure of the relative 
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increase associated with an exposure compared with a state 
of being unexposed (Feise, 2002; Perneger, 1998; Rothman, 
1990).
 All statistical analyses were conducted using the Stata 
10.0 statistical software package (StataCorp LP, College 
Station, TX). Variance estimation used a Taylor linearization 
method appropriate for the complex design of each survey. 
Signifi cance of between-survey differences in prevalence 
estimates were assessed using two-sample Z tests. Chi-square 
tests were used to assess the signifi cance of within-survey 
age-cohort effects. Reported p values refl ect comparison-
wise error rates; that is, no adjustment for multiple testing 
was introduced (Bender and Lange, 2001). The study aims 
made Type-I (false positive) and Type-II (false negative) er-
rors of equal concern.
Results
Intracohort comparisons: Lifetime and past-year prevalence 
of nonmedical prescription opioid use and prescription 
opioid-use disorder resulting from nonmedical use
 Table 1 compares equivalent birth cohorts across the two 
surveys with respect to lifetime and past-year prevalence of 
nonmedical prescription opioid use. Because lifetime pre-
scription opioid use is a cumulative behavior and we have 
controlled for the effects of population change, we expect 
the primary contribution to changes in lifetime prevalence 
between NLAES and NESARC to be new cases of pre-
scription opioid use. There were no signifi cant changes in 
lifetime use within birth cohorts as they aged (e.g., lifetime 
prevalence in the 1964-1973 birth cohort was 3.2% in the 
NLAES and 3.4% in the NESARC, 10 years later), suggest-
ing that initiation of nonmedical use of prescription opioids 
beyond age 27 (the upper limit of the youngest age category) 
is rare. Nonetheless, Table 1 also shows that past-year use 
increased among older birth cohorts between the NLAES 
and NESARC: among those born in 1944-1953 we see a 
60% increase, and among those born in 1954-1963 there 
is a 56% increase. This tendency is particularly clear when 
evaluating past-year use, conditioned on lifetime use, as 
shown in the bottom of Table 1 (e.g., there is a 64% increase 
in past-year use from the NLAES to the NESARC [20.9% 
to 34.3%] among lifetime users born in the 1954-1963 birth 
cohort). However, discrepancies in lifetime and past-year re-
ports of prescription opioid use could occur in older cohorts 
because of differential reporting of lifetime or past-year use 
with increasing age within cohorts across the two surveys, 
or there might be other forms of heterogeneity that may not 
refl ect age effects. Results were essentially unchanged when 
analyses were limited to U.S.-born subjects, eliminating im-
migration as a possible source of within-cohort change (not 
shown; available on request).
 Because lifetime prescription opioid-use disorder is a 
cumulative diagnosis, we expect the primary contribution 
TABLE 1.    Intracohort (rows) comparisons of lifetime and past-year prevalence (%) of nonmedical prescription opioid use
Age ranges (n) Estimated use, % [95% CI]
NLAES NESARC NLAES NESARC Intracohort
Birth cohort 1991-1992 2001-2002 1991-1992 2001-2002 differencea
Lifetime use
 1974-1983           – 18-27 (7,168) .       – 3.9 [3.4, 4.5] –
 1964-1973 18-27 (7,746) 28-37 (8,527) 3.2 [2.8, 3.6] 3.4 [2.9, 3.9] 6%
 1954-1963 28-37 (10,221) 38-47 (8,840) 4.2 [3.7, 4.6] 4.1 [3.6, 4.7] -2%
 1944-1953 38-47 (7,820) 48-57 (6,862) 2.8 [2.4, 3.2] 2.6 [2.1, 3.0] -7%
 1934-1943 48-57 (5,056)           – 1.1 [0.8, 1.5] .       – –
 Total (1944-1973) 18-47 (25,787) 28-57 (24,229) 3.4 [3.2, 3.7] 3.4 [3.1, 3.7] 0
Past-year use
 1974-1983           – 18-27 (7,168) .       – 2.5 [2.0, 2.9] –
 1964-1973 18-27 (7,746) 28-37 (8,527) 1.3 [1.0, 1.6] 1.6 [1.2, 1.9] 23%
 1954-1963 28-37 (10,221) 38-47 (8,840) 0.9 [0.7, 1.1] 1.4 [1.1, 1.7] 56%*
 1944-1953 38-47 (7,820) 48-57 (6,862) 0.5 [0.3, 0.7] 0.8 [0.6, 1.0] 60%*
 1934-1943 48-57 (5,056)           – 0.1 [0.0, 0.2] .       – –
 Total (1944-1973) 38-47 (7,820) 28-57 (24,229) 0.9 [0.8, 1.0] 1.3 [1.1, 1.5] 44%***
Past-year use among
lifetime users
 1974-1983           – 18-27 (255) .       – 62.5 [54.8, 69.3] –
 1964-1973 18-27 (260) 28-37 (266) 41.3 [34.5, 48.0] 46.9 [39.6, 54.3] 14%
 1954-1963 28-37 (398) 38-47 (332) 20.9 [16.6, 25.2] 34.3 [27.8, 40.8] 64%***
 1944-1953 38-47 (237) 48-57 (177) 18.2 [12.5, 23.9] 31.7 [23.8, 39.8] 74%*
 Total (1944-1973) 18-47 (895) 28-57 (775) 26.3 [23.0, 29.5] 37.9 [33.7, 42.1] 44%***
Notes: NLAES = National Longitudinal Alcohol Epidemiologic Survey; NESARC = National Epidemiologic Study on 
Alcohol and Related Conditions. aDifference between 2001-2002 (NESARC) and 1991-1992 (NLAES) lifetime preva-
lence estimates for a given birth cohort.
*p < .05; ***p < .001.
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to changes in lifetime prevalence between the two assess-
ments (NLAES [1991-1992] and NESARC [2001-2002]) 
to be new cases of prescription opioid-use disorder. Table 
2 compares equivalent birth cohorts across the two surveys 
with respect to lifetime prevalence of prescription opioid-use 
disorder. The estimated lifetime prevalence of disorder in 
the NESARC data as compared with the NLAES data was 
higher among those born between 1954 and 1963 (an 82% 
increase) and 1964 and 1973 (a 63% increase). The same 
pattern of increase for lifetime disorder between the two 
surveys was also seen when the sample was restricted to 
lifetime users (among lifetime users born in 1954-1963 there 
was an 80% increase, and among those born in 1964-1973 
there was a 53% increase).
 Changes in the estimated past-year prevalence of prescrip-
tion opioid-use disorder over the 10 years between surveys 
for similar cohorts are evaluated in Table 3. Past-year disor-
der remained stable in the 1964-1973 and 1944-1953 birth 
cohorts but signifi cantly increased among those born in 
1954-1963 (a 488% increase). An increase in the past-year 
disorder estimate for past-year users born between the years 
1954 and 1963 was also found when restricted to the sample 
of lifetime users (533% increase).
 Another notable feature of Table 3 is the strong associa-
TABLE 2.    Intracohort (rows) comparisons of lifetime prevalence of prescription opioid-use disorder
Age ranges (n) Disorder, % [95% CI]
NLAES NESARC NLAES NESARC Intracohort
Birth cohort 1991-1992 2001-2002 1991-1992 2001-2002 differencea
Lifetime disorder in
the overall population
 1974-1983           – 18-27 (7,168) .        – 1.4 [1.1, 1.8] –
 1964-1973 18-27 (7,746) 28-37 (8,527) 0.8 [0.6, 1.0] 1.3 [1.0, 1.6] 62.5%**
 1954-1963 28-37 (10,221) 38-47 (8,840) 1.1 [0.8, 1.3] 2.0 [1.6, 2.3] 81.8%***
 1944-1953 38-47 (7,820) 48-57 (6,862) 0.9 [0.6, 1.1] 1.0 [0.7, 1.3] 11.1%
 1934-1943 48-57 (5,056)           – 0.3 [0.2, 0.5] .        – –
 Total (1944-1973) 38-47 (7,820) 28-57 (24,229) 0.9 [0.8, 1.1] 1.4 [1.3, 1.6] 55.5%***
Lifetime disorder
among lifetime users
 1974-1983           – 18-27 (255) .        – 36.5 [29.1, 44.0] –
 1964-1973 18-27 (269) 28-37 (266) 24.6 [18.8, 30.4] 37.6 [30.4, 44.7] 52.8%**
 1954-1963 28-37 (398) 38-47 (332) 26.3 [21.2, 31.5] 47.3 [40.5, 54.0] 79.8%***
 1944-1953 38-47 (237) 48-57 (177) 30.6 [23.6, 37.6] 39.6 [31.2, 48.1] 29.4%
 1934-1943 48-57 (57)           – 31.1 [17.2, 45.2] .        – –
 Total (1944-1973) 18-47 (692) 28-57 (775) 26.9 [23.5, 30.3] 42.4 [32.1, 48.7] 57.6%***
Notes: NLAES = National Longitudinal Alcohol Epidemiologic Survey; NESARC = National Epidemiologic Study on 
Alcohol and Related Conditions. aDifference between 2001-2002 (NESARC) and 1991-1992 (NLAES) lifetime preva-
lence estimates for a given birth cohort.
**p < .01; ***p < .001.
TABLE 3.    Intracohort (rows) comparisons of past-year prevalence of prescription opioid-use disorder
Age ranges (n) Disorder, % [95% CI]
NLAES NESARC NLAES NESARC Intracohort
Birth year 1991-1992 2001-2002 1991-1992 2001-2002 differencea
Past-year disorder in
the overall population
 1974-1983           – 18-27 (7,168) .        – 0.6 [0.4, 0.9] –
 1964-1973 18-27 (7,746) 28-37 (8,527) 0.3 [0.2, 0.5] 0.3 [0.2, 0.4] -13%
 1954-1963 28-37 (10,221) 38-47 (8,840) 0.08 [0.03, 0.1] 0.5 [0.3, 0.7] 488%***
 1944-1953 38-47 (7,820) 48-57 (6,862) 0.1 [0.04, 0.2] 0.2 [0.05, 0.3] 25%
 1934-1943 48-57 (5,056)           – 0.04 [0.01, 0.08] .        –– –
 Total (1944-1973) 38-47 (7,820) 28-57 (24,229) 0.2 [0.1, 0.2] 0.3 [0.2, 0.4] 55%*
Past-year disorder
among lifetime users
 1974-1983           – 18-27 (255) .        – 15.8 [10.0, 21.7] –
 1964-1973 18-27 (269) 28-37 (266) 9.8 [5.4, 14.2] 8.0 [4.2, 11.8] -18%
 1954-1963 28-37 (398) 38-47 (332) 1.8 [0.6, 3.0] 11.4 [6.8, 15.9] 533%***
 1944-1953 38-47 (237) 48-57 (177) 4.4 [1.4, 7.3] 6.1 [2.1, 10.0] 38.6%
 1934-1943 48-57 (57)           – 4.0 [0.3, 7.6] .        –– –
 Total (1944-1973) 18-47 (692) 28-57 (775) 4.8 [3.2, 6.4] 9.1 [6.5, 11.6] 89.6%**
Notes: NLAES = National Longitudinal Alcohol Epidemiologic Survey; NESARC = National Epidemiologic Study 
on Alcohol and Related Conditions. aDifference between 2001-2002 (NESARC) and 1991-1992 (NLAES) past-year 
prevalence estimates for a given birth cohort.
*p < .05; **p < .01; ***p < .001.
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tion between birth cohort and past-year prevalence. In each 
survey, for past-year disorder, the prevalence is greater 
among more recent birth cohorts (upper rows) than cohorts 
born in the years before 1964 (lower rows). These patterns 
were probed further in cross-cohort analyses.
Cross-cohort comparisons: Lifetime and past-year 
prevalence of lifetime and past-year prevalence of 
prescription opioid-use disorder
 Prevalence among similar age groups can also be com-
pared across temporally adjacent birth cohort groups (Table 
4). For example, the fi rst row shows a change of 80% in the 
prevalence of lifetime disorder among 18- to 27-year-olds in 
the cohorts born between 1974 and 1983 as compared with 
those born between 1964 and 1973. Thus, these analyses 
evaluate differences between birth cohorts, while controlling 
for age. Lifetime disorder increased across almost all pairs 
of birth cohorts that were compared, which is consistent 
with a period effect, particularly among earlier birth cohorts 
(comparing those born in 1944-1953 in the NESARC versus 
those born in 1934-1943 in the NLAES, OR = 2.9, CI [1.7, 
5.1], p < .001). Past-year disorder also increased among all 
pairs of birth cohorts, especially among earlier birth cohorts 
(comparing those born in 1944-1953 in the NESARC versus 
those born in 1934-1943 in the NLAES, OR = 3.5, CI [1.2, 
10.1], p < .05).
Discussion
 The main aim of this study was to explore whether the in-
creases in prevalence of prescription opioid-use disorder re-
sulting from nonmedical use occurred across all age groups 
(period effect), occurred consistently only among younger or 
older age groups (age effect), or varied according to year of 
birth (cohort effects). We found evidence for age, period, as 
well as cohort effects.
 Indicative of age effects, prevalence of lifetime pre-
scription opioid-use disorder increased during the decade 
between surveys within most birth cohorts. In addition, 
the prevalence of past-year disorder increased across age 
in the 1954-1963 birth cohort. These fi ndings suggest that 
more problems (abuse and dependence) may emerge as 
prescription opioid users get older (age effect). For instance, 
for those in the 1954-1963 birth cohort, past-year disorder 
increased by 533% in the past decade, even though the 
number of lifetime users was essentially unchanged (398 
in the NLAES survey versus 332 in the NESARC survey). 
This pattern contrasts sharply with trends observed for other 
drugs, in which dependence generally declines with age, 
even among lifetime users (Warner et al., 1995).
 Indicative of cohort effects, lifetime as well as past-year 
prevalence of prescription opioid disorder was usually 
highest among more recent birth cohorts. For example, the 
prevalence of lifetime disorder was 1.4% among those born 
in 1974-1983 in the NESARC, compared with 0.8% among 
those born in 1964-1973 in the NLAES (when both birth 
cohorts were ages 18-27 years old). These observations sug-
gest that more recent birth cohorts are at higher risk for pre-
scription opioid problems. In addition, greater past-year use 
and disorder among more recent birth cohorts may refl ect an 
increased propensity toward chronicity among more recently 
born lifetime users. This is of concern because studies have 
shown that the majority of individuals who meet criteria for 
substance-use disorders (including prescription opioids) did 
not receive treatment for substance abuse or dependence 
(Hasin et al., 1997; Warner et al., 1995; Zacny and Lichtor, 
2008). It is also important to keep in mind that respondents 
who meet criteria for prescription opioid-use disorder re-
sulting from nonmedical use have a strong likelihood of 
also having other prescription drug-, alcohol-, and illegal 
drug-use disorders, and comorbidities need to be taken into 
account when treating these individuals (Huang et al., 2006; 
McCabe et al., 2008).
 Indicative of period effects, cross-cohort analyses of 
past-year prescription opioid-use disorder showed signifi -
cant increases in the NESARC survey as compared with the 
NLAES survey in all birth cohorts. These observations are 
consistent with a period effect; that is, the risk for prescrip-
tion opioid-use disorder increased for all individuals regard-
less of their birth cohort membership.
 Past-year prescription opioid-use disorder resulting from 
nonmedical use was consistently higher among younger 
birth cohorts, which mirrors and extends associations de-
scribed by Blanco et al. (2007), demonstrating that younger 
individuals (ages 18-34) in both surveys were more likely 
to meet criteria for prescription drug abuse/dependence. In 
addition, our study expands on fi ndings from other studies 




Age NLAES NESARC OR [95% CI]a
Lifetime disorder
 18-27 1964-1973 1974-1983 1.8 [1.2, 2.9]**
 28-37 1954-1963 1964-1973 1.2 [0.8, 1.7]
 38-47 1944-1953 1954-1963 2.3 [1.6, 3.3]***
 48-57 1934-1943 1944-1953 2.9 [1.7, 5.1]***
Past-year disorder
 18-27 1964-1973 1974-1983 2.0 [1.0, 3.9]*
 28-37 1954-1963 1964-1973 3.6 [1.5, 8.4]**
 38-47 1944-1953 1954-1963 3.8 [1.7, 8.5]**
 48-57 1934-1943 1944-1953 3.5 [1.2, 10.1]*
Notes: NLAES = National Longitudinal Alcohol Epidemiologic Survey; 
NESARC = National Epidemiologic Study on Alcohol and Related Condi-
tions. aOdds ratio for NESARC relative to NLAES; corresponds to odds 
ratio for birth years included in NESARC age group (third column), relative 
to the preceding birth cohort, which is represented in the NLAES (second 
column).
*p < .05; **p < .01; ***p < .001.
Birth years
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showing that past-year prescription opioid-use disorder has 
increased in recent years, a phenomenon that could possibly 
be linked to approval of several new opioid drug formula-
tions containing hydrocodone, oxycodone, and codeine in the 
mid- to late 1990s (U.S. General Accounting Offi ce, 2004). 
For example, oxycodone (OxyContin) was approved in 1996 
for the general U.S. population, a time between the NESARC 
and NLAES surveys. Moreover, this could be related to the 
increase in sales of prescription opioids during the same pe-
riod (Manchikanti and Singh, 2008). These drugs may have 
been diverted for nonmedical use.
 Although this study contributes to the existing literature 
on the epidemiology of prescription opioid-use disorder, 
it has a number of limitations. First, as in other national 
surveys, the measures to assess nonmedical use of opioids 
in the NLAES and NESARC did not distinguish between 
patients who misused their own medication or individuals 
who nonmedically used someone else’s opioids, or even 
whether respondents were using opioids for pain relief, to 
self-medicate psychiatric disorders, or solely as a recre-
ational drug (Boyd et al., 2006; McCabe et al., 2007, 2008; 
Zacny and Lichtor, 2008). However, fi ndings from Huang et 
al. (2006) showing a high comorbidity between prescription 
opioid-use disorders resulting from nonmedical use and il-
legal drug-use disorders could suggest that individuals who 
develop prescription opioid-use disorder after nonmedical 
use are more likely to have obtained these drugs illegally 
than legitimately via a health care provider’s prescription. 
Moreover, the NESARC and NLAES surveys did not assess 
motives for nonmedical use of opioids; thus, nonmedical us-
ers who use only for pain relief and nonmedical users who 
have other motives for use (e.g., recreational use at parties) 
are grouped together, even though they might differ in their 
propensity to have opioid use-related problems (Zacny and 
Lichtor, 2008). Further, there is no information on the source 
of the participants’ prescription opioid supplies, which may 
be unique in many aspects of use and disorders. In addition, 
respondents may signifi cantly underreport their drug use in 
face-to-face surveys (Grucza et al., 2007; Tourangeau and 
Smith, 1996), although relative trend estimates will still be 
valid if these effects are consistent across time and cohort. 
The correspondence between these trends and increases in 
the number of prescriptions written for opioids (Cicero et al., 
2007; Compton and Volkow, 2006; Van Zee, 2009; Zacny et 
al., 2003) provides further support for their validity.
 Despite its limitations, this study has several strengths. 
The NLAES and NESARC used similar methodology and 
contained nearly identical survey wording which allowed 
for valid comparisons of estimates based on data collected 
in these two national studies. Further, the inclusion of DSM-
IV criteria to assess lifetime and past-year opioid-use disor-
ders in 1991-1992 and 2001-2002 represents an important 
strength for these two national studies (McCabe et al., 2008). 
The large, nationally representative samples of the NLAES 
and NESARC allowed for calculation of national prevalence 
estimates for opioid-use disorders by birth cohort.
 In conclusion, this study’s fi ndings suggest that age, co-
hort, and period effects are related to prescription opioid-use 
disorder resulting from nonmedical use in the past decade, 
which has implications for continued etiologic investiga-
tions of prescription opioid-use disorders. Notably, data 
suggest that more recent birth cohorts are more likely to 
have prescription opioid-use disorders and that the risk for 
opioid-related problems has increased across time in all birth 
cohorts. Future national studies need to investigate further 
the health care needs and costs of treating the subpopulation 
that develops prescription opioid-use disorder.
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